Antischistosomal drugs: Past, present … and future?

doi:10.1016/0163-7258(95)00026-7

Pharmacology & Therapeutics

Volume 68, Issue 1, 1995, Pages 35-85

https://doi.org/10.1016/0163-7258(95)00026-7 Get rights and content

Abstract

The major antischistosomal drugs that have been or still are in use against infections with schistosomes are considered here together with some compounds that have not been in clinical use, but show interesting characteristics. Each individual compound presents aspects that may be enlightening about parasite biochemistry, parasite biology, and host-parasite relationships. Special attention is given to the mechanisms of action, an understanding of which is seen here as a major factor of progress in chemotherapy. Three compounds are currently in use i.e., metrifonate, oxamniquine, and praziquantel, and all three are included in the World Health Organization list of essential drugs. They are analyzed in some detail, as each one presents advantages and disadvantages in antischistosomal therapy. The reported occurrence of drugresistant schistosomes after treatment with oxamniquine and praziquantel suggests strict monitoring of such phenomena and encourages renewed efforts toward the development of multiple drugs against this human parasite.

References (322)

P Andrews
Praziquantel: mechanisms of anti-schistosomal activity
Pharmacol. Ther.
(1985)
W.A Anwar
Praziquantel (antischistosomal drug): is it clastogenic, co-clastogenic or anticlastogenic?
Mutat. Res.
(1994)
W.A Anwar et al.
Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel
Mutat. Res.
(1993)
W.A Anwar et al.
Enhancement of benzene clastogenicity by praziquantel in mice
Mutat. Res.
(1989)
P.J Brindley et al.
A genomic change associated with the development of resistance to hycanthone in Schistosoma mansoni
Mol. Biochem. Parasitol.
(1989)
P.J Brindley et al.
Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens
Mol. Biochem. Parasitol.
(1989)
J.I Bruce
New anthelmintics
Int. J. Parasitol.
(1987)
E Bueding et al.
Factors affecting the inhibition of phosphofructokinase activity of Schistosoma mansoni by trivalent organic antimonials
Biochem. Pharmacol.
(1966)
R Campos et al.
Hycanthone resistance in a human strain of Schistosoma mansoni
Trans. R. Soc. Trop. Med. Hyg.
(1976)
B.A Catto et al.
1-Thiocarbamyl-2-imidazolidinone, a metabolite of niridazole in Schistosoma mansoni
Mol. Biochem. Parasitol.
(1984)

J.B Christopherson

The successful use of antimony in bilharziosis. Administered as intravenous injections of antimonium tartaratum (tartar emetic)

Lancet

(1918)

D Cioli

Transfer of Schistosoma mansoni into the mesenteric veins of hamsters

Int. J. Parasitol.

(1976)

D Cioli et al.

Evidence for the mode of antischistosomal action of hycanthone

Life Sci.

(1985)

D Cioli et al.

Schistosoma mansoni: hycanthone/oxamniquine resistance is controlled by a single autosomal recessive gene

Exp. Parasitol.

(1992)

D Cioli et al.

Drug resistance in schistosomes

Parasitol. Today

(1993)

G.C Coles et al.

Tolerance of Kenyan Schistosoma mansoni to oxamniquine

Trans. R. Soc. Trop. Med. Hyg.

(1987)

T.A Day et al.

Praziquantel: the enigmatic antiparasitic

Parasitol. Today

(1992)

F.J de Serres

Hycanthone: an unresolved case study in risk assessment

Mutat. Res.

(1986)

Y Aden-Abdi et al.

Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood

Pharmacol. Toxicol.

(1991)

Y Aden-Abdi et al.

Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects

Bull. WHO

(1990)

W.N Aldridge et al.

History and scope of the conference

Acta Pharmacol. Toxicol.

(1981)

P Almeida Machado

The Brazilian program for schistosomiasis control

Am. J. Trop. Med. Hyg.

(1982)

P Andrews

Pharmacokinetics studies with Droncit^® in animals using a biological assay

Vet. Med. Rev.

(1976)

P Andrews

A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action

Arzneimittelforschung.

(1981)

P Andrews et al.

The in vitro uptake of ¹⁴C-praziquantel by cestodes, trematodes, and a nematode

J. Parasitol.

(1980)

P Andrews et al.

Praziquantel

Med. Res. Rev.

(1983)

Oltipraz—definitely withdrawn

Parasitol. Today

(1985)

S.S Ansher et al.

Chemoprotective effects of two dithiolethiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity

Hepatology

(1983)

S Archer

The chemotherapy of schistosomiasis

Annu. Rev. Pharmacol. Toxicol.

(1985)

S Archer et al.

Recent developments in the chemotherapy of schistosomiasis

S Archer et al.

Preparation and antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone

J. Med. Chem.

(1988)

S Archer et al.

Mode of action of the schistosomicide hycanthone: site of DNA alkylation

Mol. Biochem. Parasitol.

(1990)

V.P Argaet et al.

Cyclophilin of Schistosoma japonicum

J. Parasitol.

(1992)

A.P Baard et al.

Preliminary results in human schistosomiasis with Ro 11-3128

South Afr. Med. J.

(1979)

H.P Baer et al.

Treatment of Schistosoma mansoni- and Schistosoma haematobium-infected mice with a combination of tubercidin and nucleoside transport inhibitor

Med. Sci. Res.

(1988)

L.R Barker et al.

The possible role of acetylcholine in Schistosoma mansoni

Br. J. Pharmacol.

(1966)

M Barreau et al.

1,2-Dithiolethiones

Chem. Abstr.

(1977)

B.E Barton et al.

The immune response to a schistosomacide, amoscanate. I. Serum antibody responses

J. Immunopharmacol.

(1985)

B.E Barton et al.

The immune response to a schistosomacide, amoscanate. II. Cellmediated immune responses

J. Immunopharmacol.

(1985)

S Bassily et al.

Praziquantel for treatment of schistosomiasis in patients with advanced splenomegaly

Ann. Trop. Med. Parasitol.

(1985)

R.P Batzinger et al.

Mutagenic activities in vitro and in vivo of five antischistosomal compounds

J. Pharmacol. Exp. Ther.

(1977)

R.P Batzinger et al.

Prevention of the mutagenic activation of an antischistosomal isothiocyanate in primates by an antibiotic

Environ. Mutagen.

(1979)

B Becker et al.

Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro

Z. Parasitenk.

(1980)

J.L Bennett

Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni

J. Parasitol.

(1980)

A.B Benson

Oltipraz: a laboratory and clinical review

J. Cell. Biochem.

(1993)

Q.D Bickle et al.

Resistance following drug attenuation (Ro 11-3128 or oxamniquine) of early Schistosoma mansoni infections in mice

Parasitology

(1985)

F Blanc et al.

Le traitement des schistosomoses par les injections de 2-déhydro-émétine

Presse Méd.

(1968)

A Bloom

Studies on the mode of action of metrifonate and DDVP in schistosomes. Cholinesterase activity and the hepatic shift

Acta Pharmacol. Toxicol.

(1981)

A Bloom

PhD thesis

(1982)

J.L Blumer et al.

Relative importance of bacterial and mammalian nitroreductases for niridazole mutagenesis

Cancer Res.

(1980)

Cited by (221)

Expression profile analysis of the transient receptor potential (TRPM) channel, a possible target of praziquantel in Schistosoma japonicum
2024, Parasitology International
The WHO considers schistosomiasis, which is controlled by the mass administration of the drug praziquantel (PZQ), to be a neglected tropical disease. Despite its clinical use for over four decades, PZQ remains the only choice of chemotherapy against this disease. Regarding the previous studies that demonstrated that PZQ activates the transient receptor potential (TRP) channel in Schistosoma mansoni (Sm.TRPM_PZQ), the expression profile of the ortholog of this channel gene (Smp_246790.5) in S. japonicum (EWB00_008853) (Sj.TRPM_PZQ) was analyzed. The relative expression of this gene in various stages of the parasite lifecycle was analyzed by quantitative real-time reverse transcription-PCR (qRT-PCR), and the expression of Sj.TRPM_PZQ was observed by immunohistochemical staining using anti-serum against the recombinant Sj.TRPM_PZQ protein. qRT-PCR revealed the significantly lower mRNA expression in the snail stage in comparison to other stages (p < 0.01). The relative quantity of the Sj.TRPM_PZQ expression for paired females, unpaired males, and eggs was 60%, 56%, and 68%, respectively, in comparison to paired males that showed the highest expression (p < 0.05). Interestingly, immunostaining demonstrated that Sj.TRPM_PZQ is expressed in the parenchyma which contains muscle cells, neuronal cells and tegument cells in adult worms. This may support the two major effects of PZQ—worm paralysis and tegument disruption—induced by channel activation. Moreover, the channel was expressed in both the eggshell and the miracidia inside, but could not be observed in sporocyst. These results suggest that the expression of Sj.TRPM_PQZ corresponds to the known sensitivity of S. japonicum to PZQ.
Electrochemical Reduction of 1H-Thioxanthene-1,4,9-trione and 3-Methyl-1H-thioxanthene-1,4,9-trione – Representatives of a New Class of Heterocycles Related to Thioxanthenone
2023, European Journal of Organic Chemistry
A convenient synthetic route was proposed for the synthesis of 3‐methyl‐1H‐thioxanthene‐1,4,9‐trione. This compound and its 3‐H congener are representatives of a new class of thioxanthone‐like heterocycles, which can be used as building blocks for materials used in organic electronics. Electrochemical reduction (ECR) of 1H‐thioxanthene‐1,4,9‐trione and its 3‐methyl derivative in DMF and acetonitrile is a three‐stage process leading to the formation of the corresponding long‐lived radical anions and unstable dianions at the first and second stages, respectively. In a protolytic equilibrium, dianions are converted into 1‐oxy‐4‐hydroxy‐1H‐thioxanthene‐9‐one anions. Their one‐electron reversible ECR leads to the corresponding radical dianions, followed by the formation of (3‐methyl/H)‐1,4‐dihydroxy‐1H‐thioxantene‐9‐ones as the final products. The latter compounds can be converted into the initial (3‐methyl/H)‐1H‐thioxanthene‐1,4,9‐triones. The main intermediates were characterized using a combination of cyclic voltammetry, EPR spectroscopy, 3D spectroelectrochemistry, and DFT calculations at the (U)B3LYP/6‐31+G*/PCM level of theory. A general ECR scheme was proposed for both types of compounds.
The long road to schistosomiasis elimination in Zanzibar: A systematic review covering 100 years of research, interventions and control milestones
2023, Advances in Parasitology
Zanzibar is among the few places in sub-Saharan Africa where interruption of Schistosoma transmission seems an achievable goal. Our systematic review identifies and discusses milestones in schistosomiasis research, control and elimination efforts in Zanzibar over the past 100 years.
The search in online databases, libraries, and the World Health Organization Archives revealed 153 records published between May 1928 and August 2022. The content of records was summarised to highlight the pivotal work leading towards urogenital schistosomiasis elimination and remaining research gaps.
The greatest achievement following 100 years of schistosomiasis interventions and research is undoubtedly the improved health of Zanzibaris, exemplified by the reduction in Schistosoma haematobium prevalence from>50% historically down to<5% in 2020, and the absence of severe morbidities. Experiences from Zanzibar have contributed to global schistosomiasis guidelines, whilst also revealing challenges that impede progression towards elimination. Challenges include: transmission heterogeneity requiring micro-targeting of interventions, post-treatment recrudescence of infections in transmission hotspots, biological complexity of intermediate host snails, emergence of livestock Schistosoma species complicating surveillance whilst creating the risk for interspecies hybridisation, insufficient diagnostics performance for light intensity infections and female genital schistosomiasis, and a lack of acceptable sanitary alternatives to freshwater bodies.
Our analysis of the past revealed that much can be achieved in the future with practical implementation of integrated interventions, alongside operational research. With continuing national and international commitments, interruption of S. haematobium transmission across both islands is within reach by 2030, signposting the future demise of urogenital schistosomiasis across other parts of sub-Saharan Africa.
Natural products in the management of schistosomiasis
2023, Natural Products in Vector-Borne Disease Management
The parasitic pathogen of the genus Schistosoma causes schistosomiasis (bilharzia), which is an neglected tropical disease. It has a high risk of causing severe illness and death in humans, as well as a significant social and economic influence on South America, Southeast Asia, and predominantly, certain regions of Africa. It may be initiated by penetration of infective larvae into the skin of a human host after growth in an intermediate host (fresh water snails). This chapter consists of a brief introduction on schistosomiasis and the importance of various natural products in the management of schistosomiasis. Current treatment of schistosomiasis includes chemotherapy and prevention by praziquantel as a single medicine; additionally, oxamniquine is a prodrug used exclusively when praziquantel therapy fails. Natural products offer a source of new drugs to be developed for treatment of schistosomiasis. Living systems, i.e., plants and animals, produce natural products, and include extracts and pure compounds derived from plants, animals, and microorganisms that have kindled interest. Secondary metabolites, e.g., alkaloids, alkamides, terpenoids, lignans and neolignans, diarylheptanoids, saponins, and flavonoids are major biologically active categories of chemical constituents in a range of medicinal plants. All these secondary metabolites have unique roles and function over longer durations due to their biological activities against microorganisms and parasites. This could be one of the early points for novel research and development for schistosomiasis. The information in this collection may be useful in keeping up to date on the importance of natural products in the treatment of schistosomiasis.
Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives
2022, Molecular and Biochemical Parasitology
Praziquantel (PZQ) is the drug of choice for the treatment of all forms of schistosomiasis, although its mechanisms of action are not completely understood. PZQ acts largely on adult worms. This narrative literature review describes what is known about the mechanisms of action of PZQ against schistosomes from in vitro and in vivo studies and highlights the molecular targets in parasites and immune responses induced in definitive hosts by this drug. Moreover, new therapeutic uses of PZQ are discussed. Studies have demonstrated that in addition to impacting voltage-operated Ca2 + channels, PZQ may interact with other schistosome molecules, such as myosin regulatory light chain, glutathione S-transferase, and transient receptor potential channels. Following PZQ administration, increased T regulatory type 1 (Tr1) cell differentiation and decreased inflammation were observed, indicating that PZQ promotes immunoregulatory pathways. Although PZQ is widely used in mass drug administration schemes, the existence of resistant parasites has not been proven; however, it is a concern that should be constantly investigated in human populations. In addition, we discuss studies that evaluate health applications of PZQ (other than helminth infection), such as its effect in cancer therapy and its adjuvant action in vaccines against viruses.
Rational approach to drug discovery for human schistosomiasis
2021, International Journal for Parasitology: Drugs and Drug Resistance
Human schistosomiasis is a debilitating, life-threatening disease affecting more than 229 million people in as many as 78 countries. There is only one drug of choice effective against all three major species of Schistosoma, praziquantel (PZQ). However, as with many monotherapies, evidence for resistance is emerging in the field and can be selected for in the laboratory. Previously used therapies include oxamniquine (OXA), but shortcomings such as drug resistance and affordability resulted in discontinuation. Employing a genetic, biochemical and molecular approach, a sulfotransferase (SULT-OR) was identified as responsible for OXA drug resistance. By crystallizing SmSULT- OR with OXA, the mode of action of OXA was determined. This information allowed a rational approach to novel drug design. Our team approach with schistosome biologists, medicinal chemists, structural biologists and geneticists has enabled us to develop and test novel drug derivatives of OXA to treat this disease. Using an iterative process for drug development, we have successfully identified derivatives that are effective against all three species of the parasite. One derivative CIDD-0149830 kills 100% of all three human schistosome species within 5 days. The goal is to generate a second therapeutic with a different mode of action that can be used in conjunction with praziquantel to overcome the ever-growing threat of resistance and improve efficacy. The ability and need to design, screen, and develop future, affordable therapeutics to treat human schistosomiasis is critical for successful control program outcomes.

View all citing articles on Scopus

View full text

Antischistosomal drugs: Past, present … and future?

Abstract

Pharmacol. Ther.

Mutat. Res.

Mutat. Res.

Mutat. Res.

Mol. Biochem. Parasitol.

Mol. Biochem. Parasitol.

Int. J. Parasitol.

Biochem. Pharmacol.

Trans. R. Soc. Trop. Med. Hyg.

Mol. Biochem. Parasitol.

Lancet

Int. J. Parasitol.

Life Sci.

Exp. Parasitol.

Parasitol. Today

Trans. R. Soc. Trop. Med. Hyg.

Parasitol. Today

Mutat. Res.

Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood

Pharmacol. Toxicol.

Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects

Bull. WHO

History and scope of the conference

Acta Pharmacol. Toxicol.

The Brazilian program for schistosomiasis control

Am. J. Trop. Med. Hyg.

Pharmacokinetics studies with Droncit® in animals using a biological assay

Vet. Med. Rev.

A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action

Arzneimittelforschung.

The in vitro uptake of 14C-praziquantel by cestodes, trematodes, and a nematode

J. Parasitol.

Praziquantel

Med. Res. Rev.

Oltipraz—definitely withdrawn

Parasitol. Today

Chemoprotective effects of two dithiolethiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity

Hepatology

The chemotherapy of schistosomiasis

Annu. Rev. Pharmacol. Toxicol.

Recent developments in the chemotherapy of schistosomiasis

Preparation and antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone

J. Med. Chem.

Mode of action of the schistosomicide hycanthone: site of DNA alkylation

Mol. Biochem. Parasitol.

Cyclophilin of Schistosoma japonicum

J. Parasitol.

Preliminary results in human schistosomiasis with Ro 11-3128

South Afr. Med. J.

Treatment of Schistosoma mansoni- and Schistosoma haematobium-infected mice with a combination of tubercidin and nucleoside transport inhibitor

Med. Sci. Res.

The possible role of acetylcholine in Schistosoma mansoni

Br. J. Pharmacol.

1,2-Dithiolethiones

Chem. Abstr.

The immune response to a schistosomacide, amoscanate. I. Serum antibody responses

J. Immunopharmacol.

The immune response to a schistosomacide, amoscanate. II. Cellmediated immune responses

J. Immunopharmacol.

Praziquantel for treatment of schistosomiasis in patients with advanced splenomegaly

Ann. Trop. Med. Parasitol.

Mutagenic activities in vitro and in vivo of five antischistosomal compounds

J. Pharmacol. Exp. Ther.

Prevention of the mutagenic activation of an antischistosomal isothiocyanate in primates by an antibiotic

Environ. Mutagen.

Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro

Z. Parasitenk.

Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni

J. Parasitol.

Oltipraz: a laboratory and clinical review

J. Cell. Biochem.

Resistance following drug attenuation (Ro 11-3128 or oxamniquine) of early Schistosoma mansoni infections in mice

Parasitology

Le traitement des schistosomoses par les injections de 2-déhydro-émétine

Presse Méd.

Studies on the mode of action of metrifonate and DDVP in schistosomes. Cholinesterase activity and the hepatic shift

Acta Pharmacol. Toxicol.

PhD thesis

Pharmacokinetics studies with Droncit^® in animals using a biological assay

The in vitro uptake of ¹⁴C-praziquantel by cestodes, trematodes, and a nematode